Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-15: Inclisiran in Japanese Participants
NCT04666298Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Primary completion
- Apr 2022
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of inclisiran in hypercholesterolemia, heterozygous familial hypercholesterolemia (HeFH), sponsored by Novartis. Started Jan 2021; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiaheterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT04666298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666298.